Indication
MYC gene rearrangement
1 clinical trial
1 product
Product
Sepantronium BromideClinical trial
A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)Status: Recruiting, Estimated PCD: 2023-09-01